PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsProchlorperazine
Prochlorperazine
Compro, Prochlorperazine, Procomp (prochlorperazine) is a small molecule pharmaceutical. Prochlorperazine was first approved as Compazine on 1982-01-01. It is used to treat anxiety disorders, dementia, nausea, psychotic disorders, and schizophrenia amongst others in the USA. The pharmaceutical is active against D(3) dopamine receptor and D(2) dopamine receptor. In addition, it is known to target D(1A) dopamine receptor and D(4) dopamine receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
signs and symptoms pathological conditionsD013568
mental disordersD001523
Trade Name
FDA
EMA
Compro, Prochlorperazine, Procomp (discontinued: Compazine, Prochlorperazine)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Prochlorperazine maleate
Tradename
Company
Number
Date
Products
COMPAZINEGSKN-010571 DISCN1982-01-01
3 products, RLD
COMPAZINEGSKN-011000 DISCN1982-01-01
4 products
COMPAZINEGSKN-021019 DISCN1999-10-06
2 products
Hide discontinued
Prochlorperazine
Tradename
Company
Number
Date
Products
COMPAZINEGSKN-011127 DISCN1982-01-01
3 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
comproANDA2025-03-20
prochlorperazineANDA2025-12-17
prochlorperazine edisylateANDA2025-06-23
prochlorperazine maleateANDA2025-12-15
prochlorperazine maleate prochlorperazine maleateANDA2025-12-05
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
vomiting—D014839R11.1
nausea—D009325R11.0
dementiaEFO_0003862D003704F03
schizophreniaEFO_0000692D012559F20
psychotic disorders—D011618F20.81
anxiety disordersEFO_0006788D001008F41.1
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
— N05: Psycholeptics
— N05A: Antipsychotics
— N05AB: Phenothiazines with piperazine structure, antipsychotics
— N05AB04: Prochlorperazine
HCPCS
Code
Description
J0780
Injection, prochlorperazine, up to 10 mg
Q0164
Prochlorperazine maleate, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
S0183
Prochlorperazine maleate, oral, 5 mg (for circumstances falling under the medicare statute, use q0164)
Clinical
Clinical Trials
49 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———1————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameProchlorperazine
INNprochlorperazine
Description
Prochlorperazine is a member of the class of phenothiazines that is 10H-phenothiazine having a chloro substituent at the 2-position and a 3-(4-methylpiperazin-1-yl)propyl group at the N-10 position. It has a role as an antiemetic, a dopaminergic antagonist, an alpha-adrenergic antagonist, a cholinergic antagonist, a first generation antipsychotic, an EC 3.4.21.26 (prolyl oligopeptidase) inhibitor and a dopamine receptor D2 antagonist. It is an organochlorine compound, a N-alkylpiperazine, a N-methylpiperazine and a member of phenothiazines. It derives from a hydride of a 10H-phenothiazine.
Classification
Small molecule
Drug classTypical antipsychotic
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1
Identifiers
PDB—
CAS-ID58-38-8
RxCUI—
ChEMBL IDCHEMBL728
ChEBI ID8435
PubChem CID4917
DrugBankDB00433
UNII IDYHP6YLT61T (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
S100A4
S100A4
Organism
Homo sapiens
Gene name
S100A4
Gene synonyms
CAPL, MTS1
NCBI Gene ID
6275
Protein name
protein S100-A4
Protein synonyms
calcium placental protein, Calvasculin, fibroblast-specific protein-1, leukemia multidrug resistance associated protein, malignant transformation suppression 1, Metastasin, metastasin 1, murine placental homolog, Placental calcium-binding protein, Protein Mts1, S100 calcium-binding protein A4, S100 calcium-binding protein A4 (calcium protein, calvasculin, metastasin, murine placental homolog)
Uniprot ID
Q6ICP8
Mouse ortholog
S100a4 (20198)
protein S100-A4 (P20066)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Prochlorperazine
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 4,318 documents
View more details
Safety
Black-box Warning
Black-box warning for: Compro, Prochlorperazine, Prochlorperazine edisylate, Prochlorperazine maleate, Prochlorperazine maleate prochlorperazine maleate
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
3,710 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use